Skip to main content

Advertisement

SpringerLink
Log in

Risk-Benefit Assessment of Anticonvulsants in Women of Child-Bearing Potential

  • Review Article
  • Risk-Benefit Assessment
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Problems with anticonvulsants in women of child-bearing potential include potential adverse effects on appearance, contraception and pregnancy. These effects must be weighed against the overwhelming benefits of anticonvulsant treatment in the majority of women with epilepsy.

Coarsened features, hirsutism and acne may occur in both men and women, particularly if they are exposed to phenytoin. Valproic acid may cause weight gain and hair loss, while carbamazepine treatment carries a significant risk of skin rashes. Anticonvulsants which are liver enzyme inducers (phenytoin, phenobarbital, primidone and carbamazepine) reduce the efficacy of the oral contraceptive pill. No ‘pill failure’ has been reported with valproic acid.

There is a risk of increased seizure frequency in pregnancy irrespective of whether anticonvulsant treatment is taken. Individual seizures carry little risk to the mother or fetus but status epilepticus has a significant maternal and fetal mortality. The risk of status epilepticus must be taken into account when deciding whether to stop anticonvulsant treatment before pregnancy.

There is a 2 to 3 times increased malformation rate in the offspring of epileptic women on treatment. This is primarily due to the drug treatment, but epilepsy itself may also increase the malformation rate. Most malformations are mild and include facial clefts, congenital heart disease and skeletal abnormalities. Valproic acid, however, carries a 1% risk of causing neural tube defects: women receiving this drug who become pregnant should have an ultrasound and α-fetoprotein estimation at 16 to 18 weeks of pregnancy. If any abnormality is detected then amniocentesis should be carried out.

Women with epilepsy should be counselled before conception and during pregnancy. Before achieving pregnancy a woman should be on optimum treatment, preferably on one anticonvulsant. Consideration should be given to withdrawal of anticonvulsant drugs in any woman who has been seizure free for 2 years or who has only mild and infrequent seizures. Folate supplementation should be started prior to conception and should continue during pregnancy. There is a tendency for anticonvulsant drug concentrations to fall during pregnancy, and the dose may need to be increased if clinically indicated. Over 90% of epileptic women who become pregnant will have uneventful pregnancies and will produce healthy infants.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aarli JA. Phenytoin-induced depression of salivary IgA. Epilepsia 17: 283–291, 1976

    Article  PubMed  CAS  Google Scholar 

  • Babcock JR. Incidence of gingival hyperplasia associated with Dilantin therapy. Journal of the American Dental Association 71: 1447–1450, 1965

    PubMed  CAS  Google Scholar 

  • Backstrom T. Epileptic seizures in women related to plasma estrogen and progesterone during the menstrual cycle. Acta Neurologica Scandinavica 54: 321–347, 1976

    Article  PubMed  CAS  Google Scholar 

  • Bjerkedal T, Czeizel A, Goujard J, Kallen B, Mastroiacova P, et al. Valproic acid and spina bifida. Lancet 2: 1096, 1982

    Article  PubMed  CAS  Google Scholar 

  • Bleyer WA, Skinner AL. Fatal neonatal hemorrhage after maternal anticonvulsant therapy. Journal of the American Medical Association 235: 626–627, 1976

    Article  Google Scholar 

  • Chitayat D, Farrell K, Anderson L, Hall JG. Congenital abnormalities in two sibs exposed to valproic acid in utero. American Journal of Medical Genetics 31: 369–373, 1988

    Article  PubMed  CAS  Google Scholar 

  • Coulam CB, Annegers JF. Do anticonvulsants reduce the efficacy of oral contraceptives? Epilepsia 20: 519–526, 1979

    Article  PubMed  CAS  Google Scholar 

  • Dansky LV, Andermann E, Andermann F. Marriage and fertility in epileptic patients. Epilepsia 21: 261–271, 1980

    Article  PubMed  CAS  Google Scholar 

  • Dansky LV, Andermann E, Andermann F, Sherwin AL, Kinch RA. Maternal epilepsy and congenital malformations: correlation with maternal plasma anticonvulsant levels. In Janz et al. (Eds) Epilepsy, pregnancy and the child, pp. 251–258, Raven Press, New York, 1982

    Google Scholar 

  • Dansky LV, Andermann E, Rosenblatt D, Sherwin AL, Andermann F. Anticonvulsants, folate levels, and pregnancy outcome: a prospective study. Annals of Neurology 21: 176–182, 1987

    Article  PubMed  CAS  Google Scholar 

  • Desmond MM, Schwanecke RP, Wilson GS, Yasunaga S, Burgdorff I. Maternal barbiturate utilization and neonatal withdrawal symptomatology. Journal of Pediatrics 80: 190–197, 1972

    Article  PubMed  CAS  Google Scholar 

  • DiLiberti JH, Farndon PA, Dennis NR, Curry CJR. The fetal valproate syndrome. American Journal of Medical Genetics 19: 473–481, 1984

    Article  PubMed  CAS  Google Scholar 

  • Egger J, Brett EM. Effect of sodium valproate in 100 children with special reference to weight. British Medical Journal 283: 577–581, 1981

    Article  PubMed  CAS  Google Scholar 

  • Falconer MA, Davidson S. Course features in epilepsy as a consequence of anticonvulsant therapy. Lancet 2: 1112–1114, 1973

    Article  PubMed  CAS  Google Scholar 

  • Feldman GL, Weaver DD, Lovrien EW. The fetal trimethadione syndrome: report of an additional family and further delineation of this syndrome. American Journal of Diseases of Childhood 131: 1389–1392, 1977

    CAS  Google Scholar 

  • Friis ML. Epilepsy among parents of children with facial clefts. Epilepsia 20: 69–76, 1979

    Article  PubMed  CAS  Google Scholar 

  • Friis ML. Facial clefts and congenital heart defects in children of parents with epilepsy: genetic and environmental etiologic factors. Acta Neurologica Scandinavica 79: 433–459, 1989

    Article  PubMed  CAS  Google Scholar 

  • Friis ML, Holm NV, Sindrup EH, Fogh-Andersen P, Hauge M. Facial clefts in sibs and children of epileptic patients. Neurology 36: 346–350, 1986

    Article  PubMed  CAS  Google Scholar 

  • Gaily E, Granstrom M-L. A transient retardation of early postnatal growth in drug-exposed children of epileptic mothers. Epilepsy Research 4: 147–155, 1989

    Article  PubMed  CAS  Google Scholar 

  • Gaily E, Granstrom M-L, Hillesmaa V, Bardy A. Minor anomalies in offspring of epileptic mothers. Journal of Pediatrics 112: 520–529, 1988a

    Article  PubMed  CAS  Google Scholar 

  • Gaily E, Kantola-Sorsa E, Granstrom M-L. Intelligence of children of epileptic mothers. Journal of Pediatrics 113: 677–684, 1988b

    Article  PubMed  CAS  Google Scholar 

  • Gautray JP, Jolivet A, Goldenberg F, Tajchner G, Eberhard A. Clinical investigation of the menstrual cycle, II: neuroendocrine investigation and therapy of the inadequate luteal phase. Fertility and Sterility 29: 275–281, 1978

    PubMed  CAS  Google Scholar 

  • German J, Ehlers KH, Kowal A, De George FV, Engle MA, et al. Possible teratogenicity of trimethadione and paramethadione. Lancet 2: 261–262, 1970

    Article  PubMed  CAS  Google Scholar 

  • Gjerde IO, Strandjord RE, Ulstein M. The course of epilepsy during pregnancy: study of 78 cases. Acta Neurologica Scandinavica 78: 198–205, 1988

    Article  PubMed  CAS  Google Scholar 

  • Greenwood R, Fenwick PBC, Cunliffe WJ. Acne and anticonvulsants. British Medical Journal 287: 1669–1670, 1983

    Article  PubMed  CAS  Google Scholar 

  • Hanson JW, Myrianthopoulos NC, Harvey MAS, Smith DW. Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. Journal of Pediatrics 89: 662–668, 1976

    Article  PubMed  CAS  Google Scholar 

  • Hanson JW, Smith DW. The fetal hydantoin syndrome. Journal of Pediatrics 87: 285–290, 1975

    Article  PubMed  CAS  Google Scholar 

  • Hauser WA, Annegers JF, Anderson VE. Epidemiology and the genetics of epilepsy. In Ward et al. (Eds) Epilepsy, Raven Press, New York, 1983

  • Herzog AG, Russell V, Vaitukaitis JL, Geschwind N. Neuroendocrine dysfunction in temporal lobe epilepsy. Archives of Neurology 39: 133–135, 1982

    Article  PubMed  CAS  Google Scholar 

  • Higgins TA, Comerford JB. Epilepsy in pregnancy. Journal of the Irish Medical Association 67: 317–320, 1974

    PubMed  CAS  Google Scholar 

  • Hiilesmaa VK, Bardy A, Teramo K. Obstetric outcome in women with epilepsy. American Journal of Obstetrics and Gynaecology 152: 499–503, 1985

    CAS  Google Scholar 

  • Hiilesmaa VK, Teramo K, Granstrom M-L, Bardy AH. Foetal head growth retardation associated with maternal antiepileptic drugs. Lancet 2: 165–167, 1981

    Article  PubMed  CAS  Google Scholar 

  • Houck JC, Cheng RF, Waters MD. In Woodbury et al. (Eds) Antiepileptic drugs, pp. 267–274, Raven Press, New York, 1972

  • Janz D. On major malformations and minor abnormalities in the offspring of parents with epilepsy: review of the literature. In Janz et al. (Eds) Epilepsy, pregnancy and the child, pp. 211–222, Raven Press, New York, 1982

    Google Scholar 

  • Jones KL, Lacro RV, Johnson KA, Adams J. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. New England Journal of Medicine 320: 1661–1666, 1989

    Article  PubMed  CAS  Google Scholar 

  • Kaneko S, Otani K, Fukushima Y, Ogawa Y, Nomura Y, et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia 29: 459–467, 1988

    Article  PubMed  CAS  Google Scholar 

  • Kaneko S, Sato T, Suzuki K. The levels of anticonvulsants in breast milk. British Journal of Clinical Pharmacology 7: 624–626, 1979

    Article  PubMed  CAS  Google Scholar 

  • Kelly TE, Edwards P, Rein M, Miller JQ, Dreifuss FE. Teratogenicity of anticonvulsant drugs, II: a prospective study. American Journal of Medical Genetics 19: 435–443, 1984a

    Article  PubMed  CAS  Google Scholar 

  • Kelly TE, Rein M, Edwards P. Teratogenicity of anticonvulsant drugs, IV: the association of clefting and epilepsy. American Journal of Medical Genetics 19: 451–458, 1984b

    Article  PubMed  CAS  Google Scholar 

  • Laosombat V. Hemorrhagic disease of the newborn after maternal anticonvulsant therapy: a case report and literature review. Journal of the Medical Association of Thailand 71: 643–648, 1988

    PubMed  CAS  Google Scholar 

  • Lefebvre E, Haining RG, Labbe RF. Course facies, calvarial thickening and hyperphosphatasia associated with long-term anticonvulsant therapy. New England Journal of Medicine 286: 1301–1302, 1972

    Article  PubMed  CAS  Google Scholar 

  • Levy RH, Yerby MS. Effects of pregnancy on antiepileptic drug utilization. Epilepsia 26 (Suppl. 1): S52–S57, 1985

    Article  PubMed  Google Scholar 

  • Lindhout D, Meinardi H, Barth PG. Hazards of fetal exposure to drug concentrations. In Janz et al. (Eds) Epilepsy, pregnancy and the child, pp. 275–281, Raven Press, New York, 1982

    Google Scholar 

  • Lindhout D, Schmidt D. In-utero exposure to valproate and neural tube defects. Lancet 1: 1392–1393, 1986

    Article  PubMed  CAS  Google Scholar 

  • Mastroiacovo P, Bertollini R, Licata D, Italian Multicentric Registry of Birth Defects, Epilepsy Study Group. Fetal growth in the offspring of epileptic women: results of an Italian multicentric cohort study. Acta Neurologica Scandinavica 78: 110–114, 1988

    Article  PubMed  CAS  Google Scholar 

  • Mattson RH, Cramer JA, Darney PD, Naftolin F. Use of oral contraceptive by women with epilepsy. Journal of the American Medical Association 256: 238–240, 1986

    Article  PubMed  CAS  Google Scholar 

  • Nakane Y, Okuma T, Takahashi R, Sato Y, Wada T, et al. Multi-institutional study on the teratogenicity and fetal toxicity of antiepileptic drugs: a report of a collaborative study group in Japan. Epilepsia 21: 663–679, 1980

    Article  PubMed  CAS  Google Scholar 

  • Nau H, Rating D, Koch S, Hauser WA, Helge H. Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother’s milk and clinical status in neonates of epileptic mothers. Journal of Pharmacology and Experimental Therapeutics 219: 768–777, 1981

    PubMed  CAS  Google Scholar 

  • Niesen M, Froscher W. Finger-and toenail hypoplasia after carbamazepine monotherapy in late pregnancy. Neuropediatrics 16: 167–168, 1985

    PubMed  CAS  Google Scholar 

  • Orme M, Back DJ, Crawford P, Bowden A, Cleland P, et al. Oral contraceptive steroid therapy in patients taking anticonvulsant drugs. 4th International Symposium on Sodium Valproate and Epilepsy, pp. 236–240, Royal Society of Medicine Services Limited, 1989

  • Paskind HA, Brown M. Constitutional differences between deteriorated and nondeteriorated patients with epilepsy, I: stigmas of degeneracy. Archives of Neurology and Psychiatry 36: 1037–1044, 1936

    Google Scholar 

  • Phelan MC, Pellock JM, Nance WE. Discordant expression of fetal hydantoin syndrome in heteropaternal dizygotic twins. New England Journal of Medicine 307: 99–101, 1982

    Article  PubMed  CAS  Google Scholar 

  • Ramsay RE. Effect of hormones on seizure activity during pregnancy. Journal of Clinical Neurophysiology 4: 23–25, 1987

    Article  PubMed  CAS  Google Scholar 

  • Report on confidential enquiries into maternal deaths in England and Wales 1982–84. Report on Health and Social Subjects 34, pp. 113–114, Her Majesty’s Stationery Office, London, 1989

  • Schmidt D, Canger R, Avanzini G, Battino D, Cusi C, et al. Change of seizure frequency in pregnant epileptic women. Journal of Neurology, Neurosurgery and Psychiatry 46: 751–755, 1983

    Article  CAS  Google Scholar 

  • Shapiro S, Slone D, Hartz SC, Rosenberg L, Siskind V, et al. Anticonvulsants and parental epilepsy in the development of birth defects. Lancet 1: 272–275, 1976

    Article  PubMed  CAS  Google Scholar 

  • Straus RG, Bernstein R. Folic acid and Dilantin antagonism in pregnancy. Obstetrics and Gynecology 44: 345, 1974

    Google Scholar 

  • Strickler SM, Dansky LV, Miller MA, Seni M-H, Andermann E, et al. Genetic predisposition to phenytoin-induced birth defects. Lancet 2: 746–749, 1985

    Article  PubMed  CAS  Google Scholar 

  • Temkin O. The falling sickness, 2nd ed., p. 32, Johns Hopkins, Baltimore, 1971

    Google Scholar 

  • Teramo K, Hiilesmaa V, Bardy A, Saarikoski S. Fetal heart rate during a maternal grand mal epileptic seizure. Journal of Perinatal Medicine 7: 3–6, 1979

    Article  PubMed  CAS  Google Scholar 

  • Teramo K, Hiilesmaa VK. Pregnancy and fetal complications in epileptic pregnancies: review of the literature. In Janz et al. (Eds) Epilepsy, pregnancy and the child, pp. 53–59, Raven Press, New York, 1982

    Google Scholar 

  • Trimble MR. Serum prolactin in epilepsy and hysteria. British Medical Journal 2: 1682, 1978

    Article  PubMed  CAS  Google Scholar 

  • Walshe MM. Cutaneous drug effects in epilepsy. Transactions of St John’s Hospital Dermatological Society 58: 269–281, 1972

    CAS  Google Scholar 

  • Winter RM, Donnai D, Burn J, Tucker SM. Fetal valproate syndrome: is there a recognisable phenotype? Journal of Medical Genetics 24: 692–695, 1987

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sunderland District General Hospital, Sunderland Health Authority, Kayll Road, Sunderland, SR4 7TP, England

    Peter G. Cleland

  2. Newcastle General Hospital, Newcastle upon Tyne, England

    Peter G. Cleland

Authors
  1. Peter G. Cleland
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cleland, P.G. Risk-Benefit Assessment of Anticonvulsants in Women of Child-Bearing Potential. Drug-Safety 6, 70–81 (1991). https://doi.org/10.2165/00002018-199106010-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199106010-00007

Keywords

Search

Navigation